The Kirane Lab
DR. AMANDA KIRANE | SURGICAL ONCOLOGIST
PUBLICATIONS
Principal Investigator
Dr. Amanda R. Kirane, MD, FACS, FSSO
1. Intralesional interleukin-2 augmentation therapy in treatment-refractory melanoma. Le ST, Ji-Xu A,
Liakos W, Toussi AM, Cheng MY, Ma C, Wang EA, Wilken R, Boddu S, Downing L, Kao J, Davis JR,
Monjazeb AM, Fung MA, Konia TH, Maverakis E, Kirane A, Dermatol Ther. 2022
Nov;35(11):e15853. doi: 10.1111/dth.15853. Epub 2022 Oct 6.PMID: 36151592 No abstract available.
2. Biogeographic and disease-specific alterations in epidermal lipid composition and single-cell analysis of
acral keratinocytes. Merleev AA, Le ST, Alexanian C, Toussi A, Xie Y, Marusina AI, Watkins SM, Patel
F, Billi AC, Wiedemann J, Izumiya Y, Kumar A, Uppala R, Kahlenberg JM, Liu FT, Adamopoulos IE,
Wang EA, Ma C, Cheng MY, Xiong H, Kirane A*, Luxardi G, Andersen B, Tsoi LC, Lebrilla CB,
Gudjonsson JE, Maverakis E.JCI Insight. 2022 Aug 22;7(16):e159762. doi:
10.1172/jci.insight.159762.PMID: 35900871
3. Proprotein convertase subtilisin/kexin type 9 is a psoriasis-susceptibility locus that is negatively related
to IL36G. Merleev A, Ji-Xu A, Toussi A, Tsoi LC, Le ST, Luxardi G, Xing X, Wasikowski R, Liakos W,
Brüggen MC, Elder JT, Adamopoulos IE, Izumiya Y, Leal AR, Li Q, Kuzminykh NY, Kirane A*,
Marusina AI, Gudjonsson JE, Maverakis E.JCI Insight. 2022 Aug 22;7(16):e141193. doi:
10.1172/jci.insight.141193.PMID: 35862195
4. Comprehensive characterization of 536 patient-derived xenograft models priotizes canddiated for
targeted treatment. Sun H, Song C, Raphael B, Ding B, PDXNET Consortium**; Nat Commun 2021
Aug 24; 12(1): 5085. Doi: 10.1038/s41467-021-25177-3. *Dr. Kirane is a member of the PDXNET
Consortium
5. PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery.Koc S, Lloyd MW,
Grover JW, Xiao N, Seepo S, Subramanian SL, Ray M, Frech C, DiGiovanna J, Webster P, Neuhauser S,
Srivastava A, Woo XY, Sanderson BJ, White B, Lott P, Dobrolecki LE, Dowst H; PDXNet Consortium,
Evrard YA, Wallace TA, Moscow JA, PDXNET Consortium**; NAR Cancer. 2022 Apr
22;4(2):zcac014*Dr. Kirane is a member of the PDXNET Consortium
6. Non-surgical Management of Primary Invasive Melanoma Wang E, Ma C, Maverakis E, Kirane A. J
Dermatolog Treat. 2021 Sep 20:1-4. PMID 31747810
7. Chemotherapy After Diagnosis of Malignant Bowel Obstruction is Associated with Superior Survival
for Medicare Patients with Advanced Malignancy. Bateni SB, Gingrich AA, Kirane AR, Sauder CAM,
Gholami S, Bold RJ, Meyers FJ, Canter RJ.Ann Surg Oncol. 2021 Apr 7. doi:
10.1245/s10434-021-09831-0. Online ahead of print.PMID: 33829359*
8. Advances in Modeling the Immune Microenvironment of Colorectal Cancer. Yoon PS, Del Piccolo N,
Shirure VS, Peng Y, Kirane A, Canter RJ, Fields RC, George SC, Gholami S; Front Immunol. 2021 Feb
10;100:614300. Doi: 10.3389/fimmu.2020.614300 PMID: 33643296
9. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer
xenografts. Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R,
Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J,
Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J,
Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn
M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult
CJ, Medico E, Chuang JH; PDXNET Consortium**; EurOPDX Consortium.Nat Genet. 2021
Jan;53(1):86-99. doi: 10.1038/s41588-020-00750-6. Epub 2021 Jan 7.PMID: 33414553
*Dr. Kirane is a member of the PDXNET Consortium
10. Novel Therapeutic Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the
Immune Response Gingrich A, Kirane A. Surg Oncol Clin N Am. 2020 Jul; 29 (3): 467-483.
PMID:32482321
11. Elderly Age is Associated with More Conservative Treatment in Invasive Melanoma
Bateni S, Canter RJ, Bold RJ, Kirane A. AntiCancer Research 2020 May; 40 (5): 2895-2903. PMID
32366440
12. Association of MRI T2 Signal Intensity With Desmoid Tumor Progression During Active Observation:
A Retrospective Cohort Study. Cassidy MR, Lefkowitz RA, Long N, Qin LX, Kirane A*, Sbaity E,
Hameed M, Coit DG, Brennan MF, Singer S, Crago AM. Ann Surg. 2020 Apr;271(4):748-755. doi:
10.1097/SLA.0000000000003073.
13. The role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced
Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report.
Judge SJ, Ji J, Kirane A*, Gholami, S, Canter RJ, Cho M. Front Oncol. 2020 Apr 21; 10:581. PMID
32373540
14. Morbidity, mortality and temporal trends in the surgical management of retroperitoneal sarcoma: An
ACS-NSQIP follow-up analysis. Judge SJ, Lata-Arias K, Yanagisawa M, Darrow MA, Monjazeb
AM, Kirane AR*, Bold RJ, Canter RJ, Canter DJ. J Surg Oncol. 2019 Sep;120(4):753-760. doi:
10.1002/jso.25649.
15. Extremity Soft Tissue Sarcoma in the Elderly: Are We Overtreating or Undertreating this Potentially
Vulnerable Patient Population?" Gingrich, Bateni, Kirane*, Bold, Thorpe Canter, J Surg Oncol. 2019
Jun;119(8):1087-1098. doi: 10.1002/jso.25470.
16. Role of Radiation Therapy in Adult Extraskeletal Ewing’s Sarcoma Patients Treated with Chemotherapy
and Surgery. Saiz, Gingrich, Canter, Kirane*, Thorpe. Sarcoma. 2019 Apr 24;2019:5413527. doi:
10.1155/2019/5413527.
17. Tumor Symbiosis: Gastrointestinal Stromal Tumor as a Host for Primary Peritoneal Mesothelioma.
de la Torre J, Banerjee S, Baumgartner J, Lin GY, Burgoyne AM, Kirane A*, Sicklick J. J Gastrointest
Surg. 2019 Apr;23(4):879-881. doi: 10.1007/s11605-018-3918-3.
18. Clinical Outcomes and Costs Following Unplanned Excisions of Soft Tissue Sarcomas in the Elderly.
Bateni SB, Gingrich AA, Jeon SY, Hoch JS, Thorpe SW, Kirane AR*, Bold RJ, Canter RJ. J Surg Res.
2019 Feb 27;239:125-135. doi: 10.1016/j.jss.2019.01.055.
19. Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade
and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer.
Kirane A*, Zhang Y, Huang H, Sorrelle NB, Burrows FJ, Dellinger MT, Brekken RA. Mol Cancer Res.
2019 Feb;17(2):348-355. doi: 10.1158/1541-7786.MCR-18-0427.
20. T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with
Imiquimod and Retinoid for In-Transit Metastatic Melanoma. Ogawa H, Luxardi G, Kirane A*,
Kulkarni R, Monjazeb AM, Cheng MY, Ma C, Maverakis E. J Invest Dermatol. 2018
Jun;138(6):1442-1445. doi: 10.1016/j.jid.2017.12.027.
21. Serum C-reactive Protein and Neutrophil/Lymphocyte Ratio After Neoadjuvant Radiotherapy in Soft
Tissue Sarcoma. Yanagisawa M, Gingrich AA, Judge S, Li CS, Wang N, Thorpe SW, Kirane AR*, Bold
RJ, Monjazeb AM, Canter RJ. Anticancer Res. 2018 Mar;38(3):1491-1497.
22. Judge SJ, Kirane A, Gholami S. Intra-Arterial Hepatic Perfusion for Metastatic Melanoma of
Cutaneous Origin. Clin Surg. 2018; 3: 2165.
23. Size and Location are the Most Important Risk Factors for Malignant Behavior in Resected Solitary
Fibrous Tumors. Gholami S, Kirane A*, Brennan Annals of Surgical Oncology 2017 Dec, 24 (13):
3865-3971
24. Neoadjuvant Radiotherapy is Associated with R0 Resection and Overall Survival in Extremity Soft
tissue Sarcoma Patients Undergoing Surgery: An NCDB Analysis Gingrich AA, Bateni SB, Monjazeb
AM, Kirane A*, Canter RJ Ann of Surg Oncol 2017 Oct; 24 (11): 3252-3263
25. The modified frailty index to predict morbidity and mortality for retroperitoneal sarcoma resections.
Park JS, Bateni S, Bold RJ, Kirane A*, Canter RJ. J Surg Res 2017 Sep; 217:191-197
26. The importance of surgical margins in Retroperitoneal Sarcoma. Kirane A, Crago AM. J Surg Oncol.
2016 Mar;113(3):270-6. doi: 10.1002/jso.24135.
27. Warfarin inhibits Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and
metastases. Kirane A, Dellinger M, Lorens JB, Brekken RA.Cancer Research 2015; 75(18):3699-705
28. Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib
Kirane A, Toombs JE, Larsen J, Ostapoff KT, Schwarz RE, Burrows FJ, Brekken RA
Carcinogenesis 2012; 18:5031-42
29. Apricoxib, a novel inhibitor of COX-2 markedly improves standard therapy response in molecularly
defined models of pancreatic cancer. Clinical Cancer Research 2012; 33:1639-46
Kirane A, Toombs JE, Ostapoff KT, Carbon J, Zaknoen S, Schwarz RE, Burrows FJ, Brekken RA
30. Intradoudenal sarcoma recurrence of retroperitoneal origins, an unusual cause for duodenal obstruction.
Bao J, Mansour J, Timmerman R, Kirane A, Ewing G, Schwarz RE. World Journal of Surgical
Oncology 2012; 10:59
31. Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.
Awasthi N, Kirane A*, Schwarz M, Toombs JT, Brekken RA, Schwarz RE BMC Cancer. 2011;
11:15-9.
32. Effect of apricoxib, a novel COX-2 inhibitor, on the efficacy of standard therapy in human pancreatic
cancer cell lines. Kirane A, Carbon J, Zaknoen S, Schwarz RE, Burrows FJ, Brekken RA
Journal of Clinical Oncology 2011; 29(Suppl. 4):227
33. Preclinical antitumor activity and mechanisms of action of apricoxib, a clinical COX-2 inhibitor.
Burrows FJ, Kirane A, Carbon J, Zaknoen S, Brekken RA. Journal of Clinical Oncology 2011; 4:543
34. Biogeographic and disease-specific alterations in epidermal lipid composition and single-cell analysis of
acral keratinocytes. Merleev AA, Le ST, Alexanian C, Toussi A, Xie Y, Marusina AI, Watkins SM, Patel
F, Billi AC, Wiedemann J, Izumiya Y, Kumar A, Uppala R, Kahlenberg JM, Liu FT, Adamopoulos IE,
Wang EA, Ma C, Cheng MY, Xiong H, Kirane A, Luxardi G, Andersen B, Tsoi LC, Lebrilla CB,
Gudjonsson JE, Maverakis E.JCI Insight. 2022 Aug 22;7(16):e159762. doi:
Research Staff
Dr. M. Usman Ahmad, MD
1. Vega, E. A., Newhook, T. E., Mellado, S., Ruzzenente, A., Okuno, M., De Bellis, M., Panettieri, E., Ahmad, M. U., Merlo, I., Rojas, J., De Rose, A. M., Nishino, H., Sinnamon, A. J., Donadon, M., Hauger, M. S., Guevara, O. A., Munoz, C., Denbo, J. W., Chun, Y. S., Tran Cao, H. S., Sanchez Claria, R., Tzeng, C. D., De Aretxabala, X., Vivanco, M., Brudvik, K. W., Seo, S., Pekolj, J., Poultsides, G. A., Torzilli, G., Giuliante, F., Anaya, D. A., Guglielmi, A., Vinuela, E., Vauthey, J. Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study. Annals of Surgical Oncology 2023; 30: 4904-4911. DOI 10.1245/s10434-023-13531-2
2. Sun, B., Ahmad, M., Gingrich, A. A., Walsh, A., Nielsen, R., Maverakis, E., Kirane, A. R. The Role of AXL Tyrosine Kinase in the Melanoma Immune Microenvironment. Annals of Surgical Oncology 2022; 20 Suppl 2: 465.
3. Javadi, C., Chang, J., Forgo, E., Ahmad, M., Fisher, G. A., Chang, D. T., Delitto, D. J., Dua, M. M., Lee, B., Visser, B. C., Norton, J. A., Poultsides, G. A. Radiographic, Biochemical, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best? Annals of Surgical Oncology 2022; 20, Suppl 2: 351.
4. Lowe, M. C., Ahmad, M., Sun, B., Gholami, S., Maverakis, E., Kirane, A. R. Neoadjuvant Intralesional Therapy for High Risk Stage II Melanoma. Annals of Surgical Oncology; 20, Suppl 2: 534.
5. Ahmad, M. U., Javadi, C., Poultsides, G. A. Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer. Cancers, 2022; 14 (7). DOI 10.3390/cancers14071755.
6. Ahmad, M., Gebregziabher, B., Lee, B. Rare histologies in peritoneal carcinomatosis: a narrative review Digestive Medicine Research, 2022; 5. DOI 10.21037/dmr-22-4.
7. Jiang, Y., Zhang, Z., Wang, W., Huang, W., Chen, C., Xi, S., Ahmad, M., Ren, Y., Sang, S., Xie, J., Xiong, W., Li, T., Han, Z., Yuan, Q., Xu, Y., Xing, L., Poultsides, G., Li, G., Li, R. Biology-guided deep learning predicts prognosis and cancer immunotherapy response. Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, 2022. DOI 10.1136/jitc-2022-SITC2022.1284.
8. Ahmad, M., Riley, K. D., Ridder, T. S. Acute Colonic Pseudo-Obstruction After Posterior Spinal Fusion: A Case Report and Literature Review. World Neurosurgery, 2020; 142: 352-363. DOI 10.1016/j.wneu.2020.07.013
9. Ahmad, M., Zhang, A., Mhaskar, R. A predictive model for decreasing clinical no-show rates in a primary care setting. International Journal of Healthcare Management, 2021; 14 (3): 829-836. DOI 10.1080/20479700.2019.1698864.
10. Ahmad, M., Hanna, A., Mohamed, A., Schlindwein, A., Pley, C., Bahner, I., Mhaskar, R., Pettigrew, G. J., Jarmi, T. A Systematic Review of Opt-out Versus Opt-in Consent on Deceased Organ Donation and Transplantation (2006-2016). World Journal of Surgery, 2019; 43 (12): 3161-3171. DOI 10.1007/s00268-019-05118-4.
11. Creelan, B. C., Ahmad, M., Kaszuba, F. J., Khalil, F. K., Welsh, A. W., Ozdemirli, M., Grant, N. N., Subramaniam, D. S. Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis. Oncologist, 2019; 24 (6): 829-835. DOI 10.1634/theoncologist.2018-0505.
12. Ahmad, M., Hanna, A., Mohamed, A., Mhaskar, R., Jarmi, T., Schlindwein, A., Pley, C., Bahner, I. Increasing Organ Supply in the US: A Systematic Review of Presumed Consent vs. Informed Consent (2006-2016). American Journal of Transplantation, 2017; 17, Suppl 3: 307.
Dr. Saurabh Sharma, Ph.D.
1. Saurabh Sharma, Sudeep Sudesh Pukale, Deepak K. Sahel, Prabhjeet Singh, Manu Dalela, Sujata Mohanty, Anupama Mittal, Deepak Chitkara. "Folate targeted hybrid lipo-polymeric nanoplexes containing docetaxel and miRNA-34a for breast cancer treatment". Biomaterials Advances (Formerly knows as: Materials Science and Engineering: C) (2021). IF: 8.45
2. Saurabh Sharma, Samrat Mazumdar, Kishan S. Italiya, Tushar Date, Ram I. Mahato, Anupama Mittal, and Deepak Chitkara. "Cholesterol and Morpholine grafted cationic Amphiphilic copolymers for miRNA-34a delivery." Molecular pharmaceutics, ACS, 15, no. 6 (2018). IF: 5.36
3. Saurabh Sharma, Sudeep Sudesh Pukale, Deepak K. Sahel, Devesh S. Agarwal, Manu Dalela, Sujata Mohanty, Rajeev Sakhuja, Anupama Mittal, Deepak Chitkara. “Folate targeted cholesterol-grafted lipo-polymeric nanoparticles for chemotherapeutic agent delivery.” Springer, AAPS PharmSciTech (2020), IF: 5.36
4. Saurabh Sharma, Sudeep S. Pukale, Anupama Mittal, Deepak Chitkara. “Docetaxel and its nanoformulations: how delivery strategies could impact the therapeutic outcome?” Therapeutic delivery (2020).
5. Saurabh Sharma, Kishan Italiya, Anupama Mittal, and Deepak Chitkara. "New strategies for cancer management: how can temozolomide carrier modifications improve its delivery?" Future Science, Therapeutic delivery (2017): 475-477.
6. Sudeep S. Pukale, Saurabh Sharma, Arihant K Singh, Manu Dalela; Arihant K Singh; Sujata Mohanty; Anupama Mittal Deepak Chitkara. “Multi-component clobetasol-loaded monolithic lipid- polymer hybrid nanoparticles ameliorates imiquimod-induced psoriasis-like skin inflammation in Swiss albino mice.” Acta Biomaterialia (2020), IF: 10.63
7. Deepak Kumar Sahel, Lalitkumar K Vora, Aishwarya Saraswat, Saurabh Sharma, Jasmin Monpara , Anisha A D'Souza , Satoru Kawakita , Shahid khan, Ketan Patel, Deepakkumar Mishra , Dharmendra Khatri, Raghu Raj Singh Thakur. “CRISPR/Cas9 genome editing for tissue-specific in vivo targeting: Nanomaterials and translational perspective” Advance Science 2023, IF: 16.80
8. Satoru Kawakita, Kalpana Mandal, Lei Mou, Marvin Mecwan, Yangzhi Zhu, Shaopei Li, Saurabh Sharma, Ana Lopez Hernandez, Natan, Barros, Surjendu Maity, Praveen Bandaru, Aya Nakayama, Samad Ahadian, Han-Jun Kim, Rondinelli Donizetti Herculano, Eggehard Holler, Vadim Jucaud, Mehmet Remzi Dokmeci*, Ali Khademhosseini*. Organ-on-a-Chip Models of the Blood-Brain Barrier for Drug Discovery and Personalized Medicine. Small (Wiley). 2022. IF: 15.15
Dr. Mamatha Serasanambati, Ph.D.
1. Wu Y, Terekhanova NV, Caravan W, Naser Al Deen N, Lal P, Chen S, Mo CK, Cao S, Li Y, Karpova A, Liu R, Zhao Y, Shinkle A, Strunilin I, Weimholt C, Sato K, Yao L, Serasanambati M, etc, “Epigenetic and Transcriptomic Characterization Reveals Progression Markers and Essential Pathways in Clear Cell Renal Cell Carcinoma”, Nature Communication 2023 Mar 27;14(1):1681.
2. Cui Zhou D, Jayasinghe RG, Chen S, Herndon JM, Iglesia MD, Navale P, Wendl MC, Caravan W, Sato K, Storrs E, Mo CK, Liu J, Southard-Smith AN, Wu Y, Naser Al Deen N, Baer JM, Fulton RS, Wyczalkowski MA, Liu R, Fronick CC, Fulton LA, Shinkle A, Thammavong L, Zhu H, Sun H, Wang LB, Li Y, Zuo C, McMichael JF, Davies SR, Appelbaum EL, Robbins KJ, Chasnoff SE, Yang X, Reeb AN, Oh C, Serasanambati M, etc, “Spatially Restricted Drivers and Transitional Cell Populations Cooperate With the Microenvironment in Untreated and Chemo-Resistant Pancreatic Cancer”, Nature genetics, 2022 Aug 22.
3. Yige Wu, Nadezhda Terekhanova, Wagma Caravan, Alla Karpova, Song Cao, Siqi Chen, Houxiang Zhu, Preet Lal, Mamatha Serasanambati, etc, “Chromatin accessibility shapes tumor architecture and microenvironment in clear cell renal cell carcinoma”, Submitted to Research Square, 2022. https://doi.org/10.21203/rs.3.rs-229922/v1.
4. Mamatha Serasanambati, Yoav Y. Broza, Hossam Haick. Cell‐ Cell Cross Talk: Volatile Compounds Are Involved in Cellular Crosstalk and Upregulation. Adv. Biosys. 2019, 3 (10). Selected as a cover image in Advanced Bio-systems Journal.
5. Mamatha Serasanambati, Yoav Y. Broza, Abraham Marmur, Hossam Haick. Profiling Single Cancer Cells with Volatolomics Approach. iScience 2019, 11, 178-188. Selected as a cover image in iScience Journal.
6. Mamatha Serasanambati*, Shanmuga Reddy Chilakapati. Function of Nuclear Factor kappa B (NF-kB) in human diseases -A Review. South Indian Journal of Biological Sciences 2016; 2(4); 368-387.
7. Mamatha Serasanambati, Shanmuga C. Reddy, Pavan Kumar Manikonda, Jagadeeswara Reddy Kanala. Anticancer activity of methanolic extract of Berberis aristata in MCF -7 human breast cancer cell lines. Int. J. LifeSc. Bt & Pharm. Res. 2015; 4, (1).
8. Mamatha Serasanambati, Shanmuga C. Reddy, Jhansi Rani Vangavaragu, Damodar Reddy Chilakapati. Inhibitory effect of gemcitabine and brucine on MDA MB- 231human breast cancer cells. Int. J. Drug. Deliv. 2014; 6(2).
9. Mamatha Serasanambati, Shanmuga C. Reddy, Pavan Kumar Manikonda, Jagadeeswara Reddy Kanala, Damodar Reddy Chilakapati. Anti-cancer effects of brucine and gemcitabine combination in MCF -7 human breast cancer cells. Nat. Prod. Res. 2014; 28:1-7.
10. Mamatha Serasanambati, Shanmuga C. Reddy, Jagadeeswara Reddy Kanala, Damodar Reddy. Gemcitabine and brucine inhibit MDA MB-436 human breast cancer cells. Sch. Acad. J. Biosci. 2014; 2:71-75.
11. Mamatha Serasanambati, Shanmuga C. Reddy, Pavan Kumar Manikonda and Jagadeeswara Reddy Kanala. Curcumin potentiates antitumor effect of gemcitabine in human breast cancer in vitro. Current Trends in Biotechnology and Pharmacy 2013; 7:854-861.
12. Mamatha Reddy Serasanambati, Krishna Kumari Challa, Shanmuga C. Reddy, Raja Ratna Reddy Yakkanti, Damodar Reddy Chilakapati. Antimicrobial activity of leaf extracts of Sida cordifolia. IRJP. 2012; 3:309-311.
13. Shanmuga C. Reddy, Mamatha Serasanambati, Pavan Kumar Manikonda, Jagadeeswara Reddy Kanala. Dietary lutein attenuates bleomycin induced pulmonary fi brosis. Int. J.Durg Deliv. 2014; 6; 380-388.
14. Shanmuga C. Reddy, Mamatha Serasanambati, PrabhkarVissavajjhala, Jagadeeshwara Reddy Kanala, Damodar Reddy. Amelioration of bleomycin induced pulmonary fibrosis ina mouse model by a combination therapy of Bosentan and Imatinib. Exp. Lung. Res. 2015; 41:173 -188.
15. Shanmuga C. Reddy, Mamatha Serasanambati, Damodar Reddy, Pavan Kumar Manikonda, Ronald Ross Watson. Oral administration of Passion Fruit Peel Extract attenuates the bleomycin induced pulmonary fibrosis in mice. Can. J. Physiol. Pharmacol. 2014; 92:631 -639.
16. Shanmuga C. Reddy, Mamatha Serasanambati, Jagadeeshwara Reddy Kanala, Pavan Kumar Manikonda, D amodar Reddy. Oral administration of bosentan attenuates the bleomycin induced pulmonary fibrosis in mice. Int. J. Life Sc. Bt & Pharm. Res. 2014; 3(2).
17. Raja Ratna Reddy Yakkanti, Krishna Kumari Challa, Lokanatha Oruganti, Mamatha Serasanambati, Damodar Reddy Chilakapati. Antimicrobial activity of Azadirachta Indica (neem) leaf, bark and seed extracts. Int. J. of Res. Phytoche and Pharma, 2013; 3:1 -4.
David Jung Han Lee
1. Hidalgo, F. et al., Lee, D., Kuriyan Lab (2022). A saturation-mutagenesis analysis of the interplay between stability and activation in Ras. eLife, 11, e76595. https://doi.org/10.7554/eLife.76595.
2. Whang, S. N. et al., Lee, DJH., Duerkson-Hughes Lab (2022). Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature. Pathogens (Basel, Switzerland), 11(9), 958. https://doi.org/10.3390/pathogens11090958.
3. Chen, M., Lee, David, Wong, Becky (2023). Innovations in Diagnostic and Treatment Options for Pediatric Epilepsy and Their Anesthetic Implications. Submission accepted.
4. Whang, S. N. et al., Lee, DJH., Duerkson-Hughes Lab (2023). 30-hydroxygambogic acid increases cisplatin efficacy in an HPV+ HNSCC xenograft model. Submission pending.
5. Ahmad M. Usman, Lee David, (...), Spain, David (2023). Angioembolization for Splenic Injuries - Does it Help? A Retrospective Evaluation of Grade III-V Splenic Injuries at Two Level 1 Trauma Centers. Submission pending.
6. Lee, D., Roman, M. et al. (2023). Large Intestinal Obstruction and Perforation from Metastatic Merkel Cell Carcinoma: A Case Report and Review of Literature. Submission pending.
Sherry Hsiu-Ju Hsu
[1] Chien-Huang*, Hsiu-Ju Hsu*, Mu-En Wang et al., "Fatty acids suppress the steroidogenesis of the MA-10 mouse Leydig cell line by downregulating CYP11A1 and inhibiting late-stage autophagy," Scientific Reports 11, 12561 (2021), DOI: 10.1038/s41598-021-92008-2.